Enhancing the Cytotoxic Activity of Encorafenib Using Lipid–Polymer Hybrid Nanoparticles: An Integrated In Silico and In Vitro Evaluation
Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive cancers of brain that remains highly therapy resistant due to the presence of the blood-brain barrier and the complexity of cancer biology. Encorafenib, a strong inhibitor of BRAF, could be considered a good drug candidate for repositioning into GBM, but the poor brain permeability and efflux due to P-glycoprotein could limit its use in the clinical setting. This study aimed to evaluate the potential of encorafenib through an integrated in silico approach and enhance its in vitro cytotoxic activity using lipid–polymer hybrid nanoparticles (LPHNPs). The interaction of the compound with selected GBM targets (EPHA2, PTPRZ1, LSD1, and ALDH1A3) was analysed via molecular docking, followed by drug-likeness, ADMET, and toxicity prediction. The HTCC-LPHNPs, containing lipid core and quaternized chitosan (HTCC) shell, were developed via the nanoprecipitation technique. The cytotoxicity profile of the encorafenib-loaded nanoparticles was determined in the U87 glioblastoma cells using MTT assay, flow cytometry-based Annexin V-FITC/PI apoptosis test, and cell-cycle analysis. Encorafenib showed promising binding capabilities with the GBM-associated targets, and the strongest docking affinities were shown by LSD1 (−9.8 kcal/mol) and ALDH1A3 (−9.4 kcal/mol) targets. In silico prediction studies confirmed poor BBB penetration and P-glycoprotein substrate properties, which further emphasised the importance of a suitable drug delivery method. The optimised HTCC-LPHNPs formulation had an average particle size of 141.4 ± 2.3 nm, PDI of 0.445 ± 0.02, positive zeta potential, and 73.6 ± 1.8% entrapment efficiency with enhanced drug release in comparison with free encorafenib. More importantly, the IC₅₀ value reduced significantly from 45.71 ± 1.51 µg/mL for free encorafenib to 9.63 ± 1.27 µg/mL for HTCC-LPHNPs (p < 0.0001). Moreover, nanoparticle treatment induced apoptosis by increasing the apoptotic cells and the Sub-G1 cell population. Thus, the combined results reveal the significant increase in in vitro cytotoxic effect of encorafenib when used in combination with HTCC-LPHNPs.
Keywords: Glioblastoma; Encorafenib; Lipid–polymer hybrid nanoparticles; Quaternized chitosan; Molecular docking; Apoptosis; Cell-cycle analysis
Keywords:
Glioblastoma, Encorafenib, Lipid–polymer hybrid nanoparticles, Quaternized chitosan, Molecular docking, Apoptosis, Cell-cycle analysisDOI
https://doi.org/10.22270/jddt.v16i10.8026References
1. Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, Pineda B, Gutiérrez-Arroyo JL, et al. Glioblastoma therapy: Past, present and future. Int J Mol Sci. 2024;25(5):2529. https://doi.org/10.3390/ijms25052529 PMid:38473776 PMCid:PMC10931797
2. Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P, et al. Glioblastoma: Clinical presentation, multidisciplinary management, and long-term outcomes. Cancers (Basel). 2025;17(1):146. https://doi.org/10.3390/cancers17010146 PMid:39796773 PMCid:PMC11719842
3. Bae WH, Maraka S, Daher A. Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration. Front Oncol. 2024;14:1441460. https://doi.org/10.3389/fonc.2024.1441460 PMid:39439947 PMCid:PMC11493774
4. Giantini-Larsen AM, Pandey A, Garton ALA, Rampichini M, Winston G, Goldberg JL, et al. Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment. Neurooncol Adv. 2025;7(1):vdae201. https://doi.org/10.1093/noajnl/vdae201 PMid:39877748 PMCid:PMC11773386
5. Tang J, Karbhari N, Campian JL. Therapeutic targets in glioblastoma: Molecular pathways, emerging strategies, and future directions. Cells. 2025;14(7):494. https://doi.org/10.3390/cells14070494 PMid:40214448 PMCid:PMC11988183
6. Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48-56. https://doi.org/10.3109/07357907.2011.630050 PMid:22236189 PMCid:PMC3799884
7. Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24(1):58. https://doi.org/10.1186/s12943-025-02267-0 PMid:40011944
8. Schreck KC, Strowd RE, Nabors LB, Ellingson BM, Chang M, Tan SK, et al. Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma. Clin Cancer Res. 2024;30(10):2048-56. https://doi.org/10.1158/1078-0432.CCR-23-3241 PMid:38446982 PMCid:PMC11096001
9. Coffee E, Kaley T, Diamond E, Miller A, Schaff L. BRAFV600E-mutant glioblastoma responds to combination BRAF/MEK inhibition with encorafenib and binimetinib (P5-9.007). Neurology. 2022;98 https://doi.org/10.1212/WNL.98.18_supplement.3551
10. Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, et al. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacol Res. 2018;129:414-23. https://doi.org/10.1016/j.phrs.2017.11.006 PMid:29155017
11. Parveen S, Gupta P, Kumar S, Banerjee M. Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics. Med Drug Discov. 2023;20(100165):100165. https://doi.org/10.1016/j.medidd.2023.100165
12. Josaphat F, Fadlan A. Molecular docking of acetylacetone-based oxindole against indoleamine 2,3-dioxygenase: Study of energy minimization. Walisongo J Chem. 2023;6(2):149-57. https://doi.org/10.21580/wjc.v6i2.17638
13. Ayodele PF, Bamigbade A, Bamigbade OO, Adeniyi IA, Tachin ES, Seweje AJ, et al. Illustrated procedure to perform molecular docking using PyRx and Biovia Discovery Studio visualizer: A case study of 10kt with atropine. Prog Drug Discov Biomed Sci. 2023;6(1). https://doi.org/10.36877/pddbs.a0000424
14. Patel P, Pandhare YL, Awasthi D, Bhagat RAP, Girbane YR, Sumitha V, et al. Molecular docking analysis of quercetin, berberine, and epigallocatechin-3-gallate against key antidiabetic, antioxidant, and anti-inflammatory targets in diabetes mellitus. Genet Mol Res. 2026. https://doi.org/10.4238/8x9a9633
15. Egbuna RN, Ejiofor II, Oranu EC, Iroha IR, Uzochukwu IC. In silico identification of approved drugs for potential prophylactic uses against SARS-CoV-2 infection. Magna Sci Adv Biol Pharm. 2024;11(2):057-71. https://doi.org/10.30574/msabp.2024.11.2.0023
16. Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11(5):905-19. https://doi.org/10.1038/nprot.2016.051 PMid:27077332
17. Diakogiannaki I, D’Amore VM, Affinito A, Donati G, Cinquegrana E, Quintavalle C, et al. Targeting glioblastoma stem cells via EphA2: Structural insights into the RNA aptamer A40s for precision therapy. J Chem Inf Model. 2025;65(11):5635-48. https://doi.org/10.1021/acs.jcim.5c00295 PMid:40408544 PMCid:PMC12152952
18. Chih YC, Dietsch AC, Koopmann P, Ma X, Agardy DA, Zhao B, et al. Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen. Nat Commun. 2025;16(1):1262. https://doi.org/10.1038/s41467-025-56547-w PMid:39893177 PMCid:PMC11787355
19. Marotta G, Osti D, Zaccheroni E, Costanza B, Faletti S, Marinaro A, et al. Metabolic traits shape responses to LSD1-directed therapy in glioblastoma tumor-initiating cells. Sci Adv. 2025;11(21):eadt2724. https://doi.org/10.1126/sciadv.adt2724 PMid:40408499 PMCid:PMC13109959
20. Ganser K, Eckert F, Riedel A, Stransky N, Paulsen F, Noell S, et al. Patient-individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis. Int J Cancer. 2022;150(10):1722-33. https://doi.org/10.1002/ijc.33950 PMid:35085407
21. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717. https://doi.org/10.1038/srep42717 PMid:28256516
22. Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin Drug Discov. 2020;15(12):1473-87. https://doi.org/10.1080/17460441.2020.1798926 PMid:32735147
23. Banerjee P, Ulker O, Ozkan I, Ulker OC. The investigation of the toxicity of organophosphorus flame retardants (OPFRs) by using in silico toxicity prediction platform ProTox- 3.0. Toxicol Mech Methods. 2025;35(1):32-42. https://doi.org/10.1080/15376516.2024.2382815 PMid:39054571
24. Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform-A comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021;13(8):1291. https://doi.org/10.3390/pharmaceutics13081291 PMid:34452251 PMCid:PMC8399620
25. Valencia PM, Basto PA, Zhang L, Rhee M, Langer R, Farokhzad OC, et al. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano. 2010;4(3):1671-9. https://doi.org/10.1021/nn901433u PMid:20166699 PMCid:PMC2923464
26. Varani M, Campagna G, Bentivoglio V, Serafinelli M, Martini ML, Galli F, et al. Synthesis and biodistribution of 99mTc-labeled PLGA nanoparticles by microfluidic technique. Pharmaceutics. 2021;13(11):1769. https://doi.org/10.3390/pharmaceutics13111769 PMid:34834184 PMCid:PMC8621482
27. Abosabaa SA, Arafa MG, ElMeshad AN. Hybrid chitosan-lipid nanoparticles of green tea extract as natural anti-cellulite agent with superior in vivo potency: full synthesis and analysis. Drug Deliv. 2021;28(1):2160-76. https://doi.org/10.1080/10717544.2021.1989088 PMid:34623203 PMCid:PMC8510615
28. Elamawi RM, Al-Harbi RE, Hendi AA. Biosynthesis and characterization of silver nanoparticles using Trichoderma longibrachiatum and their effect on phytopathogenic fungi. Egypt J Biol Pest Contr. 2018;28(1). https://doi.org/10.1186/s41938-018-0028-1
29. Herrera LC, Tesoriero MV, Hermida LG. In vitro release testing of PLGA microspheres with Franz diffusion cells. Dissolut Technol. 2012;19(2):6-11. https://doi.org/10.14227/DT190212P6
30. Morgan DM. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol. 1998;79:179-83. https://doi.org/10.1385/0-89603-448-8:179 PMid:9463833
31. Henry CM, Hollville E, Martin SJ. Measuring apoptosis by microscopy and flow cytometry. Methods. 2013;61(2):90-7. https://doi.org/10.1016/j.ymeth.2013.01.008 PMid:23403105
32. Khan F, Ahmed F, Pushparaj PN, Abuzenadah A, Kumosani T, Barbour E, et al. Ajwa Date (Phoenix dactylifera L.) extract inhibits human breast adenocarcinoma (MCF7) cells in vitro by inducing apoptosis and cell cycle arrest. PLoS One. 2016;11(7):e0158963. https://doi.org/10.1371/journal.pone.0158963 PMid:27441372 PMCid:PMC4956039
33. Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, et al. Glioblastoma: Current status, emerging targets, and recent advances. J Med Chem. 2022;65(13):8596-685. https://doi.org/10.1021/acs.jmedchem.1c01946 PMid:35786935 PMCid:PMC9297300
34. Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10(1):213. https://doi.org/10.1038/s41392-025-02299-4 PMid:40628732 PMCid:PMC12238593
35. Qiu C, Sun N, Zeng S, Chen L, Gong F, Tian J, et al. Unveiling the therapeutic promise of EphA2 in glioblastoma: a comprehensive review. Discov Oncol. 2024;15(1):501. https://doi.org/10.1007/s12672-024-01380-8 PMid:39331302 PMCid:PMC11436538
36. Shen Y, Thng DKH, Wong ALA, Toh TB. Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review. Exp Hematol Oncol. 2024;13(1):40. https://doi.org/10.1186/s40164-024-00512-8 PMid:38615034 PMCid:PMC11015656
37. Shinjo K, Umehara T, Niwa H, Sato S, Katsushima K, Sato S, et al. Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma. Cancer Gene Ther. 2024;31(12):1884-94. https://doi.org/10.1038/s41417-024-00847-8 PMid:39501082 PMCid:PMC11645267
38. Stitzlein LM, Gangadharan A, Walsh LM, Nam D, Espejo AB, Singh MM, et al. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles. Front Neurol. 2023;14:1112207.
https://doi.org/10.3389/fneur.2023.1112207 PMid:37082446 PMCid:PMC10111022
39. Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, et al. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023;25(7):1249-61. https://doi.org/10.1093/neuonc/noad018 PMid:36652263 PMCid:PMC10326496
40. Müller A, Lyubarskyy B, Tchoumakov J, Wagner M, Sprang B, Ringel F, et al. ALDH1A3 contributes to radiation-induced inhibition of self-renewal and promotes proliferative activity of p53-deficient glioblastoma stem cells at the onset of differentiation. Cells. 2024;13(21):1802. https://doi.org/10.3390/cells13211802 PMid:39513909 PMCid:PMC11545341
41. Pires DEV, Blundell TL, Ascher DB. PkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066-72. https://doi.org/10.1021/acs.jmedchem.5b00104 PMid:25860834
42. de Oliveira Junior ER, Silva JM, Salomão MA, de Almeida Oliveira NC, de Freitas CS, Ferreira NN, et al. Optimized mucus adhesion and penetration of lipid-polymer nanoparticles enables effective nose-to-brain delivery of perillyl alcohol for glioblastoma therapy. Drug Deliv Transl Res. 2026;16(9):3258-73. https://doi.org/10.1007/s13346-025-01837-5 PMid:40133569
43. Akkus ZB, Nazir I, Jalil A, Tribus M, Bernkop-Schnürch A. Zeta potential changing polyphosphate nanoparticles: A promising approach to overcome the mucus and epithelial barrier. Mol Pharm. 2019;16(6):2817-25. https://doi.org/10.1021/acs.molpharmaceut.9b00355 PMid:31070926
44. Li Z, Gorfe AA. Receptor-mediated membrane adhesion of lipid-polymer hybrid (LPH) nanoparticles studied by dissipative particle dynamics simulations. Nanoscale. 2015;7(2):814-24. https://doi.org/10.1039/C4NR04834B PMid:25438167 PMCid:PMC5048752
45. Hossein abadi AR, Farhadian N, Karimi M, Porozan S. Ceftriaxone sodium loaded onto polymer-lipid hybrid nanoparticles enhances antibacterial effect on gram-negative and gram-positive bacteria: Effects of lipid - polymer ratio on particles size, characteristics, in vitro drug release and antibacterial drug efficacy. J Drug Deliv Sci Technol. 2021;63(102457):102457. https://doi.org/10.1016/j.jddst.2021.102457
46. Hassan M, Farid D, Mahdi A, Masood K, Hossein A, Morteza K. Methotrexate-Loaded PLGA Nanoparticles: Preparation, Characterization and their Cytotoxicity Effect on Human Glioblastoma U87MG Cells. Int J Med Nano Res. 2017;4(1). https://doi.org/10.23937/2378-3664/1410020
47. Marslin G, Siram K, Liu X, Khandelwal VKM, Xiaolei S, Xiang W, et al. Solid lipid nanoparticles of albendazole for enhancing cellular uptake and cytotoxicity against U-87 MG glioma cell lines. Molecules. 2017;22(11):E2040. https://doi.org/10.3390/molecules22112040 PMid:29165384 PMCid:PMC6150363
48. Liu JL, Li J, Zhang LY, Zhang PL, Zhou JL, Liu B. Preparation of N, N, N-trimethyl chitosan-functionalized retinoic acid-loaded lipid nanoparticles for enhanced drug delivery to glioblastoma. Trop J Pharm Res. 2017;16(8):1765. https://doi.org/10.4314/tjpr.v16i8.3
49. Rehman HU, Fornaciari B, Alves SR, Colquhoun A, de Oliveira Silva D. Diruthenium(II-III)-ibuprofen-loaded chitosan-based microparticles and nanoparticles systems: encapsulation, characterisation, anticancer activity of the nanoformulations against U87MG human glioma cells. J Microencapsul. 2023;40(7):549-65. https://doi.org/10.1080/02652048.2023.2258967 PMid:37698449
50. Ye H, Chen M, Cao F, Huang H, Zhan R, Zheng X. Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis. BMC Neurol. 2016;16(1):178. https://doi.org/10.1186/s12883-016-0700-6 PMid:27644442 PMCid:PMC5029068
51. Li Y, Cai T, Zhang W, Zhu W, Lv S. Effects of Saikosaponin D on apoptosis in human U87 glioblastoma cells. Mol Med Rep. 2017;16(2):1459-64. https://doi.org/10.3892/mmr.2017.6765 PMid:28627659
52. Ito R, Hamabe T, Ono M, Iwashimizu S, Inai K, Sunagawa Y, et al. 10051-cbms-4 curcumin analog Compound a inhibits the growth of Glioblastoma by inducing g2/m phase arrest and apoptosis at a lower concentration than curcumin. Neurooncol Adv. 2023;5. https://doi.org/10.1093/noajnl/vdad141.027 PMCid:PMC10710617
53. Tang Q, Ren L, Liu J, Li W, Zheng X, Wang J, et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis. Cell Prolif. 2020;53(1):e12706. https://doi.org/10.1111/cpr.12706 PMid:31642559
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Divya Zambre, Shweta Jaiswal, Ujban Md Hussain, Veena Belgamwar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.